It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
We evaluate long-term return potential across index funds to help you identify candidates with the strongest growth prospects.
28,522 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A struggling medtech name is sparking renewed optimism from analysts. This guide breaks down why a 65% upside is poss...
A famous couple's legal feud isn’t just about headlines. It can ripple into money, assets, and future plans. Here’s h...
As clean energy goals rise, two small modular reactor players, Oklo and NuScale Power, stand out. This guide breaks d...
Ralph Lauren faces a pivotal year in 2026. This article breaks down the brand's strategic moves, potential growth dri...
A retiree inherits a traditional IRA and sees Medicare premiums rise in 2026 due to a 2024 income spike, exposing the...
Two AI giants, Microsoft and Nvidia, offer very different routes to growth. This guide breaks down why one might fit ...
A retired couple weighs whether they can sustain annual trips to Japan to visit family and a yearly volunteering trip...
As Palantir hype cools, two AI-driven cash-flow engines emerge as steadier bets. This report explains why Alphabet an...
When Sony's leadership signals a fresh start for Spider-Man’s offshoot films, it’s not just a movie headline—it’s a l...
Oil jumps to $100 per barrel, sparking renewed interest in energy income strategies. This report breaks down XOMO, ML...
Dream Finders Homes expands its leadership with Steve Fischer, a banking veteran, joining the board and audit committ...